L&K Biomed Achieves World’s First Clinical Success with “BluEX-LT” at Major US Hospital

L&K Biomed, a company specializing in spinal implants, has accelerated its efforts to enter the global spinal implant market after successfully performing the world’s first spinal deformity surgery using its curved expandable cage, “BluEX-LT,” at a major US general hospital. Notably, this surgery demonstrated both improved spinal alignment and a reduced surgical range, leading to assessments that the company has presented a new treatment paradigm in the spinal deformity market, which is worth trillions of won.

On June 10, L&K Biomed announced that it had successfully completed the world’s first human clinical application surgery using “BluEX-LT” at WakeMed Health & Hospitals in North Carolina, USA.

This surgery was performed on a patient with spinal deformity, and it is significant as it marks the first-ever application of a new spinal deformity correction technique using a curved, expandable lateral cage. The case was also featured in the US spine-specialized media outlet, Becker’s Spine, drawing industry attention.

The company explained that this clinical case once again proved its differentiated technology and the potential for expansion in the field of spinal deformity treatment. In particular, the clinical efficacy of its curved, expandable cage technology, which overcomes the limitations of conventional straight cage designs, was confirmed in an actual clinical setting.

“BluEX-LT” was developed to address the structural limitations of cages previously used in lateral lumbar interbody fusion. L&K Biomed further advanced the patented curved technology applied to its previous “ExcelFix-XTP” product, maximizing the restoration of lordosis and correction of spinal alignment.

In particular, the product features a curved design that allows it to stably anchor to the edge of the vertebral endplate—the strongest supporting part of the vertebrae. This reduces the risk of implant subsidence into the vertebral body after surgery and enables more effective correction of spinal alignment in patients with scoliosis or spinal misalignment.

This surgery was performed by Dr. Gary Fletcher, a recognized authority in the field of spinal deformity surgery. Dr. Fletcher is a spinal surgeon at Bone & Joint Surgery Clinic, a specialized orthopedic medical institution in the US, and has extensive clinical experience.

For this case, Dr. Fletcher was the first to apply a new spinal deformity treatment method that combined “BluEX-LT” with his original surgical technique, “Shallow Psoas Docking”—a minimally invasive approach to the psoas muscle.

The patient had severe spinal deformity, and a wide fusion from the 10th thoracic vertebra (T10) to the first sacral vertebra (S1) above the pelvis was initially anticipated. However, after the insertion of “BluEX-LT,” the spinal alignment improved far more than expected, allowing the actual fusion range to be reduced to the second lumbar vertebra (L2) to the first sacral vertebra (S1).

This case is considered significant as it demonstrates the possibility of minimizing unnecessary thoracic fixation and preserving more natural spinal motion. It also suggests a reduction in patient burden and faster recovery.

Dr. Gary Fletcher explained, “BluEX-LT was precisely anchored to the apophyseal ring, the strong supportive structure at the edge of the vertebral endplate, and no migration of the cage was observed after surgery. The reduction in surgical range significantly decreased both operation time and blood loss, reducing the burden for both medical staff and patient.”

He added, “This is expected to have a positive impact on the patient’s recovery speed and post-surgical quality of life.”

The market views this clinical case as having important implications for the expansion of the spinal deformity treatment market. Among spinal implant segments, spinal deformity treatment is considered a high value-added area, with many complex surgeries and a growing need for advanced spinal alignment restoration technologies. As a result, demand for premium implants continues to rise.

According to global market research agencies, the adult spinal deformity market is expected to grow from approximately $2.8 billion (about KRW 3.8 trillion) in 2026 to approximately $3.9 billion (about KRW 5.3 trillion) in 2033. The next-generation spinal implant market, including expandable cages, is projected to experience rapid growth.

A representative from L&K Biomed said, “This surgery goes beyond a simple first clinical application; it is meaningful in that it confirms the potential for new treatment strategies in the spinal deformity field. As the reduction in surgical range and improvement in spinal alignment have been clinically proven, we expect this will positively influence the adoption by US medical professionals and strengthen our market leadership.”

The representative continued, “Based on this, we plan to accelerate the expansion of expandable cage adoption and the establishment of new distribution networks in the US market, securing mid- and long-term growth drivers.”

Currently, L&K Biomed is actively expanding its presence in the US spinal implant market with a diverse lineup of expandable cage products, including the “BluEX” series. Simultaneously, the company is pursuing partnerships with major global companies to build new nationwide distribution strategies across the US.

The company is also working to expand the sales network for new cervical and lumbar spine products recently approved by the US Food and Drug Administration (FDA). Through these efforts, L&K Biomed aims to diversify its US supply network and strengthen its foundation for continued growth.

This content was produced with the assistance of AI translation services.